A magnetization transfer study of mild and advanced Parkinson's disease

European Journal of Neurology

Volumn 18, Issue 3, 2011, Pages 471-477

  Tambasco, N ^a   Belcastro, V ^a,b   Sarchielli, P ^a   Floridi, P ^c   Pierguidi, L ^a,b   Menichetti, C ^a,b   Castrioto, A ^a   Chiarini, P ^c   Parnetti, L ^a   Eusebi, P ^d   Calabresi, P ^a,b   Rossi, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d Regione Umbria   (Italy)

Author keywords

Basal ganglia; Magnetic resonance imaging; Magnetization transfer ratio; Parkinson's disease; Substantia nigra; White matter

Indexed keywords

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAGNETIZATION TRANSFER RATIO; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PONS; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; THALAMUS LATERAL NUCLEUS; WHITE MATTER;

BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 79951595108     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03184.x     Document Type: Article

References (33)

1. Au WL, Adams JR, Troiano A, Stoessl AJ. Neuroimaging in Parkinson's disease. J Neural Transm 2006; 70: 241-248.
2. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 2007; 254: 185-190.
3. Sitburana O, Ondo WG. Brain magnetic resonance imaging (MRI) in parkinsonian disorders. Parkinsonism Relat Disord 2009; 15: 165-174.
4. Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003; 110: 151-169.
5. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009; 132(Pt 12): 3285-3297.
6. Wild EJ, Fox NC. Serial volumetric MRI in Parkinsonian disorders. Mov Disord 2009; 24(Suppl. 2): S691-S698.
7. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378-1384.
8. Grossman RI, Gomori JM, Ramer KN, Lexa FJ, Schnall MD. Magnetization transfer: theory and clinical applications in neuroradiology. Radiographics 1994; 14: 279-290.
9. Laule C, Vavasour IM, Whittall KP, et al. Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 2003; 250: 924-993.
10. Reidel MA, Stippich C, Heiland S, Storch-Hagenlocher B, Jansen O, Hähnel S. Differentiation of multiple sclerosis plaques, subacute cerebral ischaemic infarcts, focal vasogenic oedema and lesions of subcortical arteriosclerotic encephalopathy using magnetisation transfer measurements. Neuroradiology 2003; 45: 289-294.
11. Tambasco N, Pelliccioli GP, Chiarini P, et al. Magnetization transfer changes of grey and white matter in Parkinson's disease. Neuroradiology 2003; 45: 224-230.
12. Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004; 21: 229-235.
13. Anik Y, Iseri P, Demirci A, Komsuoglu S, Inan N. Magnetization transfer ratio in early period of Parkinson disease. Acad Radiol 2007; 14: 189-192.
14. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 1993; 39: 165-172.
15. Hanyu H, Asano T, Sakurai H, Takasaki M, Shindo H, Abe K. Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and progressive supranuclear palsy. Neuroradiology 2001; 43: 542-546.
16. Filippi M, Rocca MA. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics 2007; 4: 401-413.
17. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2005; 24: 197-211.
18. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-412.
19. Pujol J, Junque C, Vendrell P, Grau JM, Capdevila A. Reduction of the substantia nigra width and motor decline in aging and Pakinson's disease. Arch Neurol 1992; 49: 1119-1122.
20. Piccini P, Pavese N, Canapicchi R, et al. White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch Neurol 1995; 52: 191-194.
21. Sohn YH, Kim J-S. The influence of white matter hyperintensities on the clinical features of Parkinson's disease. Yonsei Med J 1998; 39: 50-55.
22. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006; 21: 223-229.
23. Spilt A, Goekoop R, Westendorp RG, Blauw GJ, de Craen AJ, van Buchem MA. Not all age-related white matter hyperintensities are the same: a magnetization transfer imaging study. AJNR Am J Neuroradiol 2006; 27: 1964-1968.
24. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78: 254-259.
25. Lewis MM, Smith AB, Styner M, et al. Asymmetrical lateral ventricular enlargement in Parkinson's disease. Eur J Neurol 2009; 16: 475-481.
26. Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery 2006; 58: 256-262.
27. 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002; 17: 917-927.
28. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
29. Rüb U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002; 23: 245-254.
30. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-24.
31. Kraft E, Loichinger W, Diepers M, et al. Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study. Parkinsonism Relat Disord 2009; 15: 558-563.
32. Starkstein SE, Merello M. The Unified Parkinson's Disease Rating Scale: validation study of the mentation, behavior, and mood section. Mov Disord 2007; 22: 2156-2161.
33. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-750.